SOURCE: UV Flu Technologies, Inc.

UV Flu Technologies, Inc.

January 13, 2010 09:00 ET

UV Flu Technologies Appoints Puravair, LLC as Master Distributor of FDA Approved Biotech Air Purification System ViraGuard UV-400

CENTERVILLE, MA--(Marketwire - January 13, 2010) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") is pleased to announce it has entered into an exclusive agreement with Puravair, LLC of Boston, MA ("Puravair") to represent the Company as the North American Master Distributor for its FDA approved, patented and highly effective germicidal air purification product, ViraGuard UV-400.

UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (estimated at over $7.7 billion in 2008). The Company manufactures the UV-400 VIRAGUARD air purification system, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to actually trap and destroy harmful microbes including Influenza A and H1N1 at rates exceeding 99.2% on a first-pass basis. The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device.

The agreement with Puravair includes logistics management of the product from the point of manufacture to the consumer. Puravair is developing a marketing program and will administer the management of a sales program in close consultation with the Company. Through Puravair's many relationships in the Health Care and Hospitality industries, they aim to develop significant penetration into numerous vertical market segments in the Professional, Medical and Commercial sectors.

Company President & CEO John Lennon comments, "We are very gratified to have the expertise, talents and reach that the management team at Puravair brings to this relationship. Their combined experiences in the development and launch of similar products, alongside a truly continent-wide reach, provides us the comfort level and latitude to continue our research, development and acquisition programs as we look towards growing our company and brand identity. Knowing that a significant aspect of our sales, marketing and distribution efforts is in the hands of this motivated team is a great way to start 2010."

Further details regarding the Company's business, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database.

About UV Flu Technologies, Inc. (OTCBB: UVFT)

UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the UV 400 VIRAGUARD, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to actually trap and destroy harmful microbes including Influenza A and H1N1 at rates exceeding 99.2% on a first-pass basis. The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device.

Notice Regarding Forward-Looking Statements

This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

ON BEHALF OF THE BOARD

UV Flu Technologies, Inc.
-----------------------------
John J. Lennon, President & CEO

Contact Information

  • Investor Information:
    Boundary Point Investor Relations, Inc.
    Toll-Free: 1-888-355-8838
    Email Contact